Novavax Gets $1.6 Bln Federal Grant For Covid-19 Vaccine

Late-stage biotech company Novavax Inc., which develops COVID-19 vaccine candidate NVX-CoV2373, will receive $1.6 billion funding under the U.S. government's Operation Warp Speed program to speed up development of the vaccine. Continuing yesterday's momentum, the stock is up 1.4 percent in premarket activity on Nasdaq.